Ralaniten

Ralaniten (also known as EPI-002) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of prostate cancer. It acts as an androgen receptor antagonist and is targeted at the N-terminal domain of the receptor.

Mechanism of Action

Ralaniten works by binding to the N-terminal domain of the androgen receptor. This is a unique mechanism of action compared to other NSAAs, which typically target the ligand-binding domain of the receptor. By targeting the N-terminal domain, Ralaniten can inhibit both the receptor's transcriptional activity and its ability to bind to androgens.

Clinical Trials

Ralaniten has been studied in phase I and II clinical trials for the treatment of prostate cancer. In these trials, it has shown promise in treating patients with castration-resistant prostate cancer, a form of the disease that is resistant to other forms of treatment.

Side Effects

As with all medications, Ralaniten may cause side effects. These can include nausea, fatigue, and diarrhea. However, these side effects are generally mild and manageable.

Future Research

Further research is needed to fully understand the potential of Ralaniten in treating prostate cancer. This includes more extensive clinical trials and studies into its long-term effects.

See Also

• Nonsteroidal antiandrogen
• Androgen receptor
• Prostate cancer

Ralaniten Resources
Latest articles Most recent articles Ongoing trials	Wikipedia